IMVIONIX Acquires U.S. and Canadian Rights to BEOVU® (brolucizumab-dbll), Marking the Company's Official Launch
Acquisition of FDA-Approved Retinal Therapy Signals IMVIONIX's Entry as a Commercial-Stage Ophthalmology Company PEACHTREE CORNERS, Ga., Nov. 10, 2026 /PRNewswire/ -- IMVIONIX Inc., a privately held biotechnology company dedicated to advancing the delivery of retinal therapies, today...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 128 stories mentioning NOV, the earliest published 7 Oct 2025.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.